Introduction
FGFs constitute a family of at least 20 structurally related proteins that signal via high affinity transmembrane receptors. These receptors are composed of two or three extracellular immunoglobulin-like domains and an intracellular tyrosine kinase domain. Currently, four distinct receptors (FGFR1-4) constitute the FGFR family, with multifunctional specificity generated by cell-and tissue-specific alternative processing of the receptor primary transcripts. 1 It is generally believed that aberrant expression of the specific growth factors or their receptors in a variety of cell types can confer a growth advantage and thus contribute to a tumorigenic phenotype. Dysregulated ligand/receptor interactions that have led to malignant transformation of cells were found for several members of the FGF family. Although they act as signalling molecules in developing mouse embryos, FGF-3 (int-2), FGF-4 (hst/kFGF) and FGF-5 are considered oncogenes due to their ability to induce solid tumors in adults. 2 FGF-2, a prototype member of the FGF family was, aside from its developmental significance, implicated as a potential regulator of tumor growth. 3 In this context, FGF-2 production was detected in various tumor cell lines, and elevated concentrations of FGF-2 in plasma and/or urine have been found in patients with active tumors of different origin, including leukemias. [4] [5] [6] In solid tumors a role for FGF-2 is well justified already by its ability to act as an inducer of vascular permeability and as a specific mitogen for endothelial cells. However, this mechanism does not necessarily have to be the most critical in clonal malignancies of the hematopoietic system. Accumulation of malignant cell clone(s) in bone marrow, lymph nodes, spleen, and blood is the major characteristics of leukemia disease. However, the attempts to experimentally document growth-promoting activity of FGF-2 on leukemia cells in vitro, even when these were not terminally differentiated, have been largely unsuccessful.
In this study, several parameters that are relevant to the responsiveness of leukemia cells to FGF-2 were investigated in a large sample of patients and healthy individuals. These parameters included: (1) the level of plasma FGF-2 and its correlation to the type of disease; (2) the spectrum of molecular mass isoforms of FGF-2 in peripheral WBCs; (3) the expression of functional ligand-binding FGFRs in patients' WBCs; (4) the phosphorylation of MEK and ERK kinases in response to FGF-2 stimulation in WBCs; and (5) in vitro growth and viability of WBCs upon treatment with FGF-2.
Materials and methods

Sample collection and processing
Peripheral blood was collected from consenting patients or healthy donors by venipuncture into EDTA-coated tubes. Plasma samples were clarified by centrifugation (for 5 min at 10 000 g and 4°C), aliquoted, and stored at −70°C. Peripheral WBCs were isolated using osmotic lysis (0.155 M NH 4 Cl, 0.01 M NH 4 HCO 3 , 0.1 mM EDTA) of erythrocytes. Cells were then washed twice with Ca 2+ -and Mg 2+ -free phosphatebuffered saline (PBS), pH 7.2. After a final centrifugation, cell pellets were subjected to further analysis.
The leukemia cell lines, K562, HL60, U937, and the carcinoma cell line, HeLa, were all propagated in RPMI 1640 medium (Gibco/BRL, Gaithersburg, MD, USA) supplemented with 10% fetal calf serum (Gibco/BRL), 50 M ␤-mercaptoethanol, 100 U/ml penicillin and 100 g/ml streptomycin in 5% CO 2 at 37°C. For all subsequent analyses, cultured cells were processed in the same way as peripheral WBCs.
Determination of FGF-2 in peripheral blood
Two commercially available sandwich ELISA-based kits (Quantikine High Sensitivity and Quantikine; R&D Systems, Wiesbaden, Germany) were employed to determine the concentration of FGF-2 in plasma samples. The upper limits of detection of FGF-2 using these kits are 64 pg/ml and 640 pg/ml, and the minimal detectable doses are 1 pg/ml and 10 pg/ml, respectively. Each sample was measured at least in duplicate, according to the manufacturer's instructions. The same assay was adopted for determining the concentration of FGF-2 in conditioned media.
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Western blot analysis
For Western blot analysis of molecular variants of FGF-2, cells were extracted in RIPA buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS, 1 mM phenylmethylsulfonyl fluoride, 0.2 M aprotinin, 100 U/ml DNAse I) for 30 min at 4°C. Protein concentrations were measured using the DC protein assay (BioRad, Hercules, CA, USA), total amounts of protein were equalized, and samples were mixed with 2× Laemmli sample buffer and heated for 5 min at 95°C and immediately subjected to 14% SDS-PAGE. After electrophoresis, proteins were transferred on to polyvinylidene difluoride (PVDF) membrane (Amersham Pharmacia Biotech, Buckinghamshire, UK) and probed with mouse monoclonal anti-FGF-2-antibody (Sigma, St Louis, MO, USA). This was followed by incubation with sheep polyclonal anti-mouse IgG horseradish peroxidase-conjugated antibody (Sigma). The FGF-2 bands were then visualized using ECL Plus enhanced chemiluminiscence reagents (Amersham).
Isolation of FGF-2 from plasma and conditioned medium
Two to five ml of plasma, or 10 ml of RPMI 1640 culture medium conditioned by 1 × 10 7 WBCs for 5 days, were gently rocked with heparin-coated agarose beads (20 l, 4% beads; Sigma) overnight at 4°C. The beads were then washed twice with either PBS (for plasma) or serum-free medium (for conditioned medium), and boiled with 2× Laemmli sample buffer for 3 min. The samples were centrifuged (for 3 min at 5000 g) and supernatants were assayed for FGF-2 by Western blotting.
Reverse transcriptase-polymerase chain reaction analysis
Total RNA was isolated from WBCs using the RNeasy mini kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. Random-primed cDNA was synthesized from 500 ng of total RNA using M-MLV reverse transcriptase (TopBio, Prague, Czech Republic). The primer pairs used for specific PCR amplification of FGFR1-4 sequences were as follows: FGFR1 IIIb (forward, 5′-CATTGTGGAGAATGAGTACG-3′; reverse, 5′-TCTGGTGACAGTGAGCCA-3′; 385 bp); FGFR1 IIIc (forward, 5′-GCTGGAGTTAATACCACCGACAAAG-3′; reverse, 5′-GGGTTTGCCTAAGACCAGTCTGTC-3′, 510 bp); FGFR2 IIIb (forward, 5′-AAGCAGGAGCATCGCATTGG-3′; reverse, 5′-CCTCGGTCACATTGAACAGAGC-3′; 400 bp); FGFR2 IIIc (forward, 5′-CCATGCGGTGGCTGAAAAAC-3′; reverse, 5′-CAGCGTCCTCAAAAGTTACATTCC-3′; 450bp); FGFR3 IIIb (forward, 5′-CGGCAGACGTACACGCTG-3′; reverse, 5′-CGTGAACGCTCAGCCAAAAG-3′; 358 bp); FGFR3 IIIc (forward, 5′-ACACCCTACGTTACCGTGCTCAAG-3′; reverse, 5′-AGGATGCCTGCATACACACTGC-3′; 224bp); FGFR4 (forward, 5′-GACCTCCAGCAACGATGATGAG-3′; reverse, 5′-GTCTTTAGGACTTGCACATAGGGG-3′; 558 bp).
All PCR reactions were performed using Taq DNA Polymerase (Top-Bio) as follows: for 30 cycles with denaturation at 94°C for 15 s, annealing (at a specific temperature for each primer pair) for 30 s, and synthesis at 72°C for 45 s. In the last 15 cycles, synthesis time was elongated by 5 s, and the last synthesis time was 5 min. The products were subjected to 2% agarose gel electrophoresis and visualized by ethidium bromide staining. Authenticity of PCR products was verified Leukemia by manual DNA sequencing (Thermo Sequenase Cycle Sequencing kit; Amersham).
Receptor binding assay
To determine specific receptor binding of FGF-2 in B-CLL and CML peripheral WBCs and control cell lines, 1-4 × 10 6 cells were incubated for 90 min at 4°C with 1 ng/ml 125 I-FGF-2 (Amersham; specific activity 1300 Ci/mmol) in a total volume of 1 ml RPMI 1640 supplemented with 25 mM Hepes pH 7.0 and 0.15% BSA, on an end-over-end mixer. To control for non-specific ligand binding, we used unlabelled competitor FGF-2 (1-1000 ng/ml) and heparin (Sigma, grade I-A from porcine intestinal mucosa; 10 ng/ml-10 g/ml). After incubation, the cells were washed twice with cold RPMI 1640, and samples of washed cells were counted for gamma emission for 3 min (Gamma Counter Tesla, Pardubice, Czech Republic). Non-specific binding was estimated from the residual counts in the presence of unlabelled FGF-2 and heparin at concentrations of 500 ng/ml and 10 g/ml, respectively, concentrations which were found to compete maximally with the binding of iodinated FGF-2. In order to estimate specific binding of FGF-2, these values of non-specific binding were subtracted from the total counts obtained with 1 ng/ml 125 I-FGF-2. All assays were performed at least in triplicate.
Phosphorylation assay
To determine the activity of MEK 1/2 and ERK 1/2, WBCs were serum starved for 3 h and then subjected to various treatments with synthetic MEK inhibitor PD98059 (50 M; New England Biolabs, Beverly, MA, USA), FGF-2 (1, 10 or 100 ng/ml), or serum (10%) for 10 and 60 min at 37°C in 5% CO 2 . Cells were then washed with cold PBS containing 1 mM sodium orthovanadate and harvested into boiling 2× Laemmli sample buffer. Each experiment was carried out using 1 × 10 6 cells in a 10 ml culture tube. Samples were then boiled for an additional 4 min, subjected for 10% sodium dodecyl sulphatepolyacrylamide gel electrophoresis (SDS-PAGE), and transferred on to a PVDF membrane. The phosphorylation state of MEK and ERK was assessed by probing with anti-phospho-MEK 1/2 (Ser217/221) antibody and anti-phospho-p44/42 ERK1/2 (Thr202/Tyr204) antibody, respectively (New England Biolabs). In order to compare the level of unphosphorylated kinases in differentially treated cells, PVDF membranes were stripped using 62.5 mM Tris-HCl, pH 6.8, 2% SDS and 100 mM mercaptoethanol, washed and re-immunoblotted with anti-MEK 1/2 or p44/42 ERK 1/2 antibodies (New England Biolabs). Detection of phosphorylated and unphosphorylated kinases was done using horseradish peroxidaseconjugated antibody and a chemiluminiscence detection system (ECL Plus; Amersham).
Proliferation and cell viability assays
WBCs were suspended in RPMI 1640 containing 5% fetal calf serum (previously depleted of heparin-binding growth factors by overnight incubation with an excess of heparin-agarose beads), 50 M ␤-mercaptoethanol, 100 U/ml penicillin, 100 g/ml streptomycin, and various concentrations of human recombinant FGF-2 (Sigma). Cells were then seeded Leukemia at an initial density of 1 × 10 5 /well (B-CLL) or 5 × 10 4 /well (CML) in 96-well tissue culture plates (Nunc, Roskilde, Denmark) and cultured for 1, 3 or 5 days. Following each period of culture, 10% cell proliferation reagent WST-1 (Boehringer Mannheim, Germany) was added to each well and plates were incubated for 3.5 h at 37°C. The absorbance of formazan dye that is produced by metabolically active cells was quantified spectrophotometrically at 450 nm with a reference wavelength of 690 nm.
In a parallel experiment we determined cell viability using a dye exclusion assay. WBCs maintained under the same culture conditions as described above were incubated with propidium iodide (2 g/ml) for 5 min following each period of culture, and then the proportion of positive/dead and negative/living cells was determined by flow cytometry (FACSCalibur; Becton Dickinson, San Jose, CA, USA).
Results
Levels of FGF-2 are elevated in plasma of CML and B-CLL patients
Peripheral blood was collected from 83 patients with various neoplastic disorders of the hematopoietic system, comprising B-CLL (n = 39), CML (n = 16), myelodysplastic syndrome (MDS; n = 3), acute myeloid leukemia (AML; n = 14), acute lymphoblastic leukemia (ALL; n = 6), hairy cell leukemia (HCL; n=5), and also from 11 healthy individuals. The highest level of plasma FGF-2 in the group of healthy individuals reached 22.9 pg/ml (range 1.0-22.9 pg/ml, mean 9.2 pg/ml). These concentrations fit into the range prescribed by the manufacturer of the ELISA kit as typical for healthy individuals (range 0-26.7 pg/ml, mean 10.9 pg/ml); and concentrations of FGF-2 exceeding 30 pg/ml were classified as elevated. Based on these criteria, no abnormality in the level of plasma FGF-2 was found in any patient with MDS, AML, ALL, or HCL ( Figure 1 ). As shown in Figure 1 and Table 1 , however, the level of plasma FGF-2 was significantly increased in 21 of 39 patients suffering from B-CLL, and in seven of 16 patients suffering from CML. Moreover, while in CML the levels were always below 100 pg/ml, seven blood samples in the B-CLL group contained more than 100 pg/ml, with the maximum reaching 1392 pg/ml.
As increased levels of FGF-2 may be found in the blood of patients with liver cirrhosis, 7 in phenytoin-treated patients suffering from epilepsy, 8 and in patients with systemic sclerosis and dermatomyositis, 9 we therefore checked for these diseases in the clinical history of CML and B-CLL patients. None of the individuals involved in this study suffered from any of those diseases and/or from tumor duplicity at the time of collection of peripheral blood.
B-CLL, but not CML WBCs, synthesize multiple isoforms of FGF-2 and secrete low molecular mass FGF-2
As WBCs represent a potential source of plasma FGF-2, we determined the presence of FGF-2 isoforms in WBCs of B-CLL and CML patients having either normal or elevated concentrations of FGF-2 in their peripheral blood (Figure 2a) . The validity of the assay was proven using human HeLa and K562 cells as positive controls, and the HL60 cells as negative control.
10-12 Among 39 WBC samples in the B-CLL group, 30
Figure 1
Concentrations of FGF-2 in plasma. Summary of the results obtained from 94 donors, including 11 healthy individuals. Plasma samples were assayed for FGF-2 by ELISA systems, and each data point was derived from at least two measurements. All values below the dashed line were considered normal, whereas values above this line were classified as elevated. Seven data points for B-CLL patients marked by an arrow were measured using the Quantikine High Sensitivity kit (upper limit of detection is 64 pg/ml), estimated as у64 pg/ml, and were not reassayed using the less sensitive Quantikine kit (upper limit of detection is 640 pg/ml) due to insufficient plasma samples. samples (77%) contained high amounts of both nuclear (22, 24 kDa) and secretable (18 kDa) isoforms of FGF-2, and nine samples contained much lower amounts of these isoforms. Notably, and according to Rai classification, the donors of these nine (low FGF-2) WBC samples were all in the early stage of the disease (two were in stage 0, four in stage I, and three in stage II), and none showed elevated concentrations of FGF-2 in their peripheral blood. In addition to the 18, 22 and 24 kDa FGF-2 isoforms, an additional band of approximately 18.5 kDa was detected by an anti-FGF-2 antibody in B-CLL WBCs as well as in K562 cells.
To determine whether or not FGF-2 can be secreted, B-CLL and K562 cells were cultured for 5 days and the resulting conditioned medium was subjected to heparin-based enrichment of heparin-binding growth factors followed by Western blot analysis. As shown in Figure 2b , secretable FGF-2 isoforms were recovered from media conditioned by B-CLL and control K562 cells. As we were able to recover the same 18.5 kDa band as was revealed in the WBCs of B-CLL patients (Figure 2b ), this band most likely represents a post-translationally modified 18 kDa form of FGF-2. We further determined the amounts of FGF-2 in conditioned media using ELISA. This showed that B-CLL WBCs begin to secrete measurable amounts of FGF-2 (13 pg/ml) soon after plating (5 h), and Sex, age, diagnosis, stage of the disease (for B-CLL according to Rai classification), and its treatment are indicated for all patients analyzed. The concentrations of FGF-2 exceeding 30 pg/ml are given in bold. The concentrations given as Ͼ64 pg/ml were determined using the Quantikine High Sensitivity kit (upper limit of detection is 64 pg/ml) and could not be remeasured using the Quantikine kit allowing broader range of measurement (10-640 pg) because of the shortage of plasma. All measurements were done at least in duplicate. that the level of FGF-2 increases after 72 h to up to 72 pg/ml of culture medium which contained an initial density of 1 × 10 6 cells/ml. Therefore, at least in vitro, B-CLL peripheral WBCs are able to secrete low molecular mass FGF-2.
Leukemia
This result was not obtained for WBCs in CML. Although, Leukemia using Western blotting, we routinely detected less than 80 pg of human recombinant FGF-2 per lane, in WBCs of CML patients we detected only 24 kDa FGF-2 at moderate levels, as was found for healthy individuals, and for individuals suffering from diseases other than B-CLL (Figure 2a) . We therefore conclude that in CML there are other cellular sources of plasma low molecular mass FGF-2.
Peripheral B-CLL and CML WBCs express multiple FGFR mRNAs
The quality of the potential response of WBCs to FGF-2 would be dependent on their receptor outfit. It was previously shown that FGFRs (except FGFR4) present multiple splice variants in their ligand binding site, the extracellular C-terminal half of immunoglobulin (Ig) domain 3; and that several specific changes in the expression of these binding sites are related to malignant transformation. [13] [14] [15] [16] Therefore, extensive analysis of splicing variants of Ig domain 3 was undertaken in order to obtain the most detailed insight into the expression of FGFRs in WBCs recovered from B-CLL patients, CML patients, and control healthy individuals. K562 and U937 human cell lines were used for comparison because of their well-documented expression of multiple FGFR variants. 12 Overall, the data summarized in Table 2 demonstrate that WBCs are equipped with receptors for FGF-2 in both healthy and leukemic individuals.
Peripheral WBCs in CML and B-CLL differ in their capacity to bind, and to respond, to exogenous FGF-2
Finally, we addressed two key questions regarding the biological role of FGF-2 in leukemia. We asked whether or not FGFRs in WBCs of B-CLL and CML patients recognize exogenous FGF-2, and whether or not the anticipated occupancy of FGFR by its ligand can cause a cellular response. Four in vitro assays were adopted.
Firstly, we determined the ability of WBCs to bind 125 I-FGF-2. There was at least a two-fold difference between B-CLL and CML in the binding of Secondly, we examined the effect of FGF-2 on phosphorylation of two mitogen-activated protein kinases (MEK and ERK) in B-CLL and CML samples. Figure 4 shows an example of this experiment. Treatment with FGF-2 does not elicit a response in B-CLL WBCs (Figure 4a) . In CML WBCs, however, phosphorylation of both kinases was significantly increased by FGF-2 in the concentration range of 1-100 ng/ml, with a maximal response 10 min after addition of the growth factor (Figure 4b ). These striking data suggest that the presence of high levels of soluble FGF-2 in plasma of CML patients affects the protein kinase transduction pathways in peripheral WBCs, and that this downstream activation, very likely FGFRmediated, may modulate the final cellular response.
Thirdly, we tested the proliferation response of WBCs to I-FGF-2 binding in the presence of 500 ng/ml FGF-2 and 10 g/ml heparin (black columns). K562 cells, which are known to bind specifically FGF-2 with high affinity, are included as a positive control. As a further control we have tested U937 cells, which do not express specific receptors for FGF-2. Each value represents an average of three independent measurements with the calculated standard deviation.
Figure 4
Analysis of MEK and ERK kinase activity in (a) one B-CLL and (b) two CML WBC samples stimulated with exogenous FGF-2. B-CLL and CML WBCs were treated as indicated above each panel. The cell extracts were prepared after 10 and 60 min treatments, and solubilized proteins were subjected to Western blotting. The activity of the MEK and ERK kinases was determined by phospho-specific anti-MEK and ERK antibodies. The same blots were reprobed with anti-MEK and ERK antibodies to show the equality of loaded samples. (a) In B-CLL WBCs, phosphorylated MEK was almost undetectable. The phosphorylation of ERK kinase was suppressed by MEK inhibitor PD98059 (after 10 and 60 min) or serum (after 10 min), but was not affected by FGF-2. (b) In contrast, WBCs collected from CML patients respond to short-term treatment with 1 ng/ml FGF-2 (patient 1), or 10 and 100 ng/ml FGF-2 (patient 2) by very significant phosphorylation of both kinases. Again, inhibitor PD98059 suppresses activation of ERK kinase as does serum. In the case of patient 1, FGF-2 at a high concentration of 100 ng/ml also causes ERK dephosphorylation. Such dephosphorylation of ERK can be explained by a very short mitogenic stimulus, which is followed by rapid activation of the downstream signalling cascade, and thus dephosphorylation of the first intracellular targets.
Figure 5
Effect of exogenous FGF-2 on growth of WBCs recovered from (a) six B-CLL and (b) four CML patients. WBCs isolated from B-CLL and CML patients were maintained for 1, 3 and 5 days in culture media supplemented with 1, 20 and 100 ng/ml FGF-2, respectively. Nontreated cultures served as a control. Growth of WBCs is expressed as the absorbance obtained by measuring their metabolic activity using WST-1 as a substrate. Each bar represents the mean of 10 replicate samples. The significance of the differences between FGF-2-treated WBCs and nontreated controls was evaluated by analysis of variance (*; P Ͻ 0.05). Standard deviations are indicated. (a) One potentially FGF-2-responding WBC sample (6) and five nonresponding WBC samples (1, 2, 3, 4, 5) were found in the B-CLL group. (b) Three potentially FGF-2-responding WBC samples (2, 3, 4) and one nonresponding WBC sample (1) were found in the CML group. exogenously added FGF-2 ( Figure 5 ). WBCs collected from six B-CLL and four CML patients were cultured with or without recombinant FGF-2 for 5 days. Three concentrations, 1, 20 and 100 ng/ml of FGF-2, were selected. Colorimetrical quantification of the conversion of WST-1 into formazan was used as a measure of the number of metabolically active cells. Among six B-CLL patients, WBCs of only one patient (No. 6) weakly augmented their growth upon culture with FGF-2, and this effect was apparent at the concentration of 20 ng/ml FGF-2. In CML patients we found that WBCs were stimulated to grow in three out of four cases (Nos. 2, 3 and 4), but only one sample of WBCs unambiguously augmented its growth upon FGF-2 treatment. Therefore, we may only hypothesize that there could be a proliferation response of leukemia cells to FGF-2 in vivo. This result, together with the convincing results obtained in the phosphorylation assays, supports our contention of a mitogenic activity of plasma FGF-2 in CML patients.
Fourthly, to test whether or not FGF-2 might affect WBCs viability or increase cell survival, the viability upon culture with and without recombinant FGF-2 was compared using a dye exclusion assay in four B-CLL and four CML patients. The results (Figure 6 ), interpreted as the percentage of living cells 
Discussion
Here, we show for the first time that a certain percentage of patients suffering from CML (but not from MDS, AML, ALL and HCL) contain abnormally high amounts of FGF-2 in their blood plasma, similar to levels found previously in individuals suffering from B-CLL. 5, 17 Moreover, we provide data showing that peripheral WBCs in both subtypes of leukemic disease are capable of synthesizing FGF-2. There is still, however, a major difference between B-CLL and CML WBCs in the spectrum of molecular mass isoforms of FGF-2 that they contain. It should be noted that, in general, FGF-2 can be synthesized in several high (HMM) and low (LMM) molecular mass isoforms. The LMM isoform (18 kDa) FGF-2 accumulates in the cytoplasm prior to secretion, while three HMM isoforms (22, 22.5 and 24 kDa) are localized predominantly in the nucleus. 18, 19 There is experimental evidence that the receptordependent paracrine and autocrine activities of FGF-2 are mediated by the 18kDa isoform, while HMM isoforms of FGF-2 have an intracrine, receptor-independent mode of action.
20,21 LMM FGF-2 typically regulates cell growth and migration. 22 In contrast, HMM FGF-2 isoforms which have been found in various immortalized and transformed cell lines 23 were shown to confer: (1) decreased sensitivity to radiation-induced cell death; 24 (2) an immortal phenotype; 25 (3) resistance to apoptosis; and (4) the ability to grow in lowserum conditions. 26 Importantly, we found that many patients in the B-CLL group characteristically display high concentrations of FGF-2 in their plasma and high amounts of multiple FGF-2 isoforms in their WBCs, whilst strongly secrete the 18 kDa FGF-2 from their WBCs. Based on this correlation we hypothesize that peripheral WBCs constitute a major source of FGF-2 in the blood of patients afflicted with this subtype of leukemia. In contrast to B-CLL, WBCs recovered from CML patients contained only small amounts of the 24 kDa isoform of FGF-2, although the level of soluble FGF-2 in plasma was significantly increased. While searching for the potential source of FGF-2 in the blood of these patients, we first excluded the possibility of a concomitant occurrence of solid tumors and noncancer diseases. Nevertheless, other possible sources of FGF-2 in plasma of CML patients should be considered. One of them is the rapidly proliferating blasts that are present in bone marrow, while being rare in peripheral blood. During progression of CML, especially in its terminal stages, large numbers of proto-differentiated blasts are released into the bloodstream. As we did not detect any secretable form of FGF-2 in peripheral WBCs of two CML patients who were in terminal blast crisis, this possibility is unlikely. Alternatively, based on the previous work of Brunner et al, 27 the most obvious source of FGF-2 in bone marrow are the stromal fibroblasts; these cells may also contribute to the high levels of FGF-2 observed in the blood of B-CLL patients. In support of this, Dalley et al 28 found that patients afflicted with idiopathic myelofibrosis, which is manifested by rapidly proliferating fibroblasts, also have elevated concentrations of FGF-2 in their blood.
To address the significance of elevated plasma FGF-2, we We then examined the influence of FGF-2 on MEK and ERK phosphorylation in B-CLL and CML WBCs. We have shown, for the first time, that B-CLL WBCs do not respond (two out of two WBC samples), while CML WBCs respond rapidly, to exogenous FGF-2 (two out of two WBC samples). Furthermore, we revealed some FGF-2 concentration-dependent differences in the phosphorylation pattern of both kinases among CML patients' WBC samples. We believe that the same activation may also occur in vivo. On the other hand, the FGF-2 must be present at very high concentrations in order to activate MEK and ERK in CML-derived cells, which certainly also express the MAP kinase cascade-activating Bcr-Abl fusion proteins p190 and p210. 38 We also measured the in vitro responsiveness of both B-CLL and CML WBCs to exogenous FGF-2 as another way of judging the biological significance of FGF-2 in vivo. We found only weak response to exogenously added FGF-2 in one B-CLL patient out of six studied, consistent with their low 125 I-FGF-2 binding activity and inability to activate the MAP kinase cascade. This observation most likely means that, besides its possible autocrine action, FGF-2 secreted by WBCs in B-CLL is targeted to some other non-WBC cell population. We speculate, however, that under specific conditions such as those induced by 'therapeutic stress', WBCs in B-CLL might respond to FGF-2 in vivo. This idea stems from the data of Menzel et al 17 and Konig et al 39 demonstrating that exogenously added FGF-2 acts as a survival factor that protects cells from, for example, fludarabide-induced cell death. In support of results obtained in our phosphorylation assay, the data from the proliferation test with CML WBCs suggest a different action of FGF-2. Upon exposure to FGF-2, WBCs were significantly stimulated to proliferate in one of four patients, and less effectively in two. Notably, this action of exogenous FGF-2 shows some dose-dependent activity. Unfortunately, we can only speculate which cell type(s) produces FGF-2, and also which cell type(s) responds to FGF-2 in a diverse cell population that is typical for this type of leukemic disease.
Finally, we did not detect any difference in cell viability between untreated and FGF-2-treated B-CLL and CML WBCs. The aim of this investigation was to reveal the effect of FGF-2 on susceptibility to apoptosis in CML cells that show activated MAP kinases. Our presumption was based on recent studies showing constitutive activation of MAP kinases in acute leukemias 40 and the role of MAP kinases in resistance to apoptosis in Bcr/Abl expressing K562 leukemia cells. 41 Our observations indicate that the data derived from K562 cells cannot be simply extrapolated to a very heterogenous population of WBCs freshly collected from CML patients.
In future work, we shall determine whether or not the FGF-2 produced and secreted by peripheral WBCs in B-CLL has some autocrine activity, and we shall identify the population among all peripheral WBCs which is stimulated by circulating FGF-2 in CML patients.
